You are now leaving This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
You are now leaving


Currently in Phase II Clinical Development

Area of focus:

Achalasia and Sickle Cell Disease
Dysregulation of the nitric oxide-soluble guanylate cyclase-cyclical guanosine monophosphate (NO-sGC-cGMP) signaling pathway is believed to be linked to multiple vascular and fibrotic diseases, such as achalasia and sickle cell disease.

Our candidate:

IW-1701 is an investigational soluble guanylate cyclase (sGC) stimulator from Ironwood’s diverse library of sGC stimulators, which are being investigated for their potential effects on vascular and fibrotic diseases. The compound has been shown in nonclinical studies to modulate the NO-sGC-cGMP signaling pathway and is currently being evaluated in a Phase II study in achalasia. IW-1701 is wholly-owned by Ironwood Pharmaceuticals.

« Back to Pipeline